Andrej Janež
University Medical Centre Ljubljana, Slovenia · University Medical Centre Ljubljana
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Andrej Janež as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 09:58 UTC. Open this list on ClinicalTrials.gov
- Ph4NCT07354880 · Effect of Tirzepatide on Cardiovascular and Metabolic Parameters in Obese Adult Patients With Congenital Heart DiseaseUniversity Medical Centre Ljubljana · not yet recruiting · Obesity & Overweight, Adult Congenital Heart Disease · study director
- N/ANCT05147896 · Semaglutide Anti-Atherosclerotic Mechanisms of Action Study in Type 2 Diabetes PatientsUniversity Medical Centre Ljubljana · unknown · Diabetes Mellitus, Type 2, Atherosclerosis · principal investigator
- Ph4NCT02941445 · Weight Maintenance With Dipeptidyl Peptidase 4 (DPP4) Inhibitor Sitagliptin in Combination With Metformin After Liragludite Induced Weight LossUniversity Medical Centre Ljubljana · completed · Polycystic Ovary Syndrome, Body Weight · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 09:58 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 09:58 UTC. The ranking covers the 200 most relevant of 29 PubMed records, and a shared surname and initials can bring in a namesake. All 29 on PubMed
- Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10).Diabetes Metab · 2020320 citationsRCR 16.6
- Liraglutide increases IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments: a pilot randomized study.Eur J Endocrinol · 2018162 citationsRCR 7.7
- Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment.N Engl J Med · 2020146 citationsRCR 7.4
- Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin.Eur J Endocrinol · 2014136 citationsRCR 5.1
- Short term monotherapy with GLP-1 receptor agonist liraglutide or PDE 4 inhibitor roflumilast is superior to metformin in weight loss in obese PCOS women: a pilot randomized study.J Ovarian Res · 201587 citationsRCR 3.4
- Semaglutide delays 4-hour gastric emptying in women with polycystic ovary syndrome and obesity.Diabetes Obes Metab · 202386 citationsRCR 11.0
- A 12-week treatment with the long-acting glucagon-like peptide 1 receptor agonist liraglutide leads to significant weight loss in a subset of obese women with newly diagnosed polycystic ovary syndrome.Hormones (Athens) · 201585 citationsRCR 3.4
- Empagliflozin on top of metformin treatment improves arterial function in patients with type 1 diabetes mellitus.Cardiovasc Diabetol · 201881 citationsRCR 3.6
- Short-term intervention with liraglutide improved eating behavior in obese women with polycystic ovary syndrome.Endocr Res · 201569 citationsRCR 2.8
- Genetic variability in GLP-1 receptor is associated with inter-individual differences in weight lowering potential of liraglutide in obese women with PCOS: a pilot study.Eur J Clin Pharmacol · 201567 citationsRCR 2.2